Dataset Information


Phase I study of Veliparib in combination with Cisplatin and Vinorelbine for patients with advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer

ABSTRACT: PURPOSE: Preclinically, cisplatin is synergistic with vinorelbine and the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib, and has anti-neoplastic activity in TNBC and BRCA mutation-associated breast cancer. This phase I study assessed veliparib with cisplatin and vinorelbine. PATIENTS AND METHODS: A 3+3 dose escalation design evaluated veliparib administered BID for 14 days with cisplatin (75 mg/m2 day 1) and vinorelbine (25 mg/m2 days 1,8) every 21 days, for six to ten cycles, followed by veliparib monotherapy. Pharmacokinetics, measurement of poly(ADP-ribose) in peripheral blood mononuclear cells, and preliminary efficacy were assessed. Immunohistochemistry and gene expression profiling were performed to evaluate potential predictors of response. Thirty-nine samples were assessed, six samples were run as technical duplicates. Two of the samples had a high rate of missing probes and were excluded during the normalization/pre-processing. Each sample represents a pre- or post-treatment breast cancer specimen from individual patients.

ORGANISM(S): Homo sapiens

PROVIDER: E-GEOD-72795 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2015-09-09 | E-GEOD-72795 | ArrayExpress
| S-EPMC4911292 | BioStudies
| S-EPMC5933261 | BioStudies
| S-EPMC5290001 | BioStudies
| S-EPMC4232081 | BioStudies
| S-EPMC4298385 | BioStudies
| S-EPMC7580251 | BioStudies
| S-EPMC6338394 | BioStudies
| S-EPMC3986598 | BioStudies
| S-EPMC5618936 | BioStudies